

EORTC 1702-LCG-ROG Targeted therapy with or without dose-intensified radioterapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors

Markus Glatzer

Targeted therapy beyond Progression with or without dose-intensified radioterapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors (HALT)

Objectives: To determine wether in patients with Mutation positive advanced NSCLC the use of SBRT to ≤ 3 sites of OPD with continuation of TKI improves Progression free survival (PFS) compared with continuation of TKI alone.

Target: 110 Patients for Phase II component

type of project	clinical studies
status	scheduled
start of project	2019
end of project	2025
study design	Multicenter, Randomized Phase II / III Trial
responsible person	Dr. Markus Glatzer